![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1300841
¼¼°èÀÇ Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : ¿öÅ©Ç÷ο캰, Ä¡·á ¿µ¿ªº°, ¾àÁ¦ À¯Çüº°, ¼ºñ½º À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ºÐ¼®(2023-2030³â)Global Drug Discovery Outsourcing Market Size study & Forecast, by Workflow, by Therapeutics Area, by Drug Type (Small Molecules, Large Molecules ), by Service Type, by End user and Regional Analysis, 2023-2030 |
¼¼°èÀÇ Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀåÀº 2022³â¿¡ ¾à 35¾ï ´Þ·¯·Î Æò°¡µÇ¸ç, ¿¹Ãø ±â°£ÀÎ 2023-2030³â¿¡´Â 7.5% ÀÌ»óÀÇ °ÇÀüÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.
Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀåÀº Á¦¾à±â¾÷À̳ª ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ÀÌ Drug Discovery ¿¬±¸°³¹ß ÇÁ·Î¼¼½ºÀÇ ´Ù¾çÇÑ ´Ü°è¸¦ CRO(ÀÓ»ó½ÃÇè¼öʱâ°ü)³ª ±âŸ Àü¹® ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿¡ ¾Æ¿ô¼Ò½ÌÇÏ´Â °ÍÀ» °¡¸®Åµ´Ï´Ù. Ÿ±ê ½Äº°, È÷Æ® Åõ ¸®µå ÃÖÀûÈ, ÀüÀÓ»ó ½ÃÇè, ÀÓ»ó½ÃÇè, ±ÔÁ¦±â°ü¿¡ ´ëÇÑ ½Åû µî Drug Discovery¿¡ °ü·ÃµÈ ƯÁ¤ ¾÷¹«³ª Ã¥ÀÓÀ» ¿ÜºÎ¿¡ ¸Ã±â°Ô µË´Ï´Ù. ¼¼°èÀÇ Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀº ½ÉÇ÷°üÁúȯÀÇ À¯º´·ü »ó½Â°ú °í·ÉÀÚ Àα¸ÀÇ Áõ°¡ÀÔ´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ½ÃÀå ±â¾÷¿¡ ÀÇÇÑ ±¸»óÀÇ Áõ°¡¿Í Á¦Á¦ÀÇ Áøº¸°¡ ¿¹Ãø ±â°£ Áß ¼¼°èÀÇ Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå¿¡ À¯¸®ÇÑ ¼ºÀå ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù.
ÀÌ Áö¿ª¿¡¼´Â ½ÉÇ÷°üÁúȯ, ¾Ï, È£Èí±âÁúȯ µî ¸¸¼ºÁúȯÀÇ ºÎ´ãÀÌ Å« °ÍÀ¸·Î ÀÎÇØ Drug Discovery ¾Æ¿ô¼Ò½Ì ºÐ¾ßÀÇ ½ÃÀå ¼ºÀåÀÌ ±â´ëµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¸é CDC National Center for Health Statistics¿¡ µû¸£¸é 2021³â ½ÃÁ¡¿¡ ¹Ì±¹ÀÇ 18¼¼ ÀÌ»ó ¼ºÀÎÀÇ 4.9%°¡ °ü»óµ¿¸Æ¼º ½ÉÁúȯÀ» ¾Î°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡´Â ¾ÈÀüÇϰí È¿°úÀûÀÎ Ä¡·á¹ýÀÇ °³¹ß¿¡ ´ëÇÑ ¼ö¿äÀÇ Áõ°¡¸¦ âÃâÇϸç, ÀÌ¿¡ µû¶ó ¿¬±¸°³¹ß ¼öŹ ±â°ü(CRO)°úÀÇ Çù·Â Çʿ伺À» °¡¼Ó½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¦ÈÞ³ª Àμö¸¦ Æ÷ÇÔÇÑ ÁÖ¿ä ±â¾÷¿¡ ÀÇÇÑ Àü·«Àû ±¸»óÀº ÀÌ Áö¿ª¿¡¼ Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±¸»óÀÇ ÀϷʷμ 2022³â 1¿ù¿¡ Shanghai Fosun Pharmaceutical(Group) Co., Ltd¿Í Insilico Medicine »çÀÌ¿¡ ü°áµÈ Á¦ÈÞ °è¾àÀ» µé ¼ö ÀÖ½À´Ï´Ù. ÀÌ Á¦ÈÞ´Â InsilicoÀÇ AI ÁÖµµ Drug Discovery¡¤°³¹ß ´É·ÂÀ» Ȱ¿ëÇÏ¿© ´Ù¾çÇÑ ¼¼°è Ç¥ÀûÀ» Ÿ±êÀ¸·Î ÇÏ´Â ÀǾàǰ âÃâÀ» ÃßÁøÇÏ´Â °ÍÀ» ¸ñÀûÀ¸·Î Çϰí ÀÖ½À´Ï´Ù. ÀÌ Á¦ÈÞ¿¡¼´Â 4°³ÀÇ »ý¹°ÇÐÀû Ç¥Àû ¿¬±¸°³¹ß¿¡ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸°³¹ß Á¦ÈÞ ÇÁ·ÎÁ§Æ®¿¡ 1,300¸¸ ´Þ·¯°¡ ÅõÀڵǾú½À´Ï´Ù. ±×·¯³ª Drug Discovery ¾Æ¿ô¼Ò½ÌÀÇ °íºñ¿ëÀÌ 2023-2030³âÀÇ ¿¹Ãø ±â°£ Áß ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù.
¼¼°èÀÇ Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå Á¶»ç¿¡¼ °í·ÁÇÑ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÔ´Ï´Ù. ºÏ¹Ì´Â È®¸³µÈ Á¦¾à±â¾÷À̳ª ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ÀÇ Á¸Àç¿¡ ÀÇÇØ Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ¹Ì±¹Àº ¾Æ¿ô¼Ò½Ì »ê¾÷ÀÌ È°¹ßÇϰí, ±ÔÁ¦ ȯ°æµµ °®Ãß¾îÁö°í ÀÖÀ¸¹Ç·Î ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÷´Ü ÀÇ·á ÀÎÇÁ¶ó, °·ÂÇÑ ¿¬±¸°³¹ß ´É·Â, ½Å±Ô Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿äÀÇ Áõ°¡¶ó´Â ¿äÀÎÀÌ ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº Drug Discovery ¾Æ¿ô¼Ò½Ì ½ÃÀå¿¡¼ ±Þ¼ÓÇÑ ¼ºÀåÀ» ´Þ¼ºÇϰí ÀÖ½À´Ï´Ù. Áß±¹, Àεµ, ÀϺ», Çѱ¹ µîÀÇ ±¹°¡°¡ ÁÖ¿ä ¾Æ¿ô¼Ò½Ì Çãºê·Î¼ ºÎ»óÇϰí ÀÖÀ¸¸ç, ÁÖ¿ä ÀÌÀ¯´Â ¸¹Àº Àα¸, ºñ¿ë¸éÀÇ ¿ìÀ§¼º, »ý¸í°úÇÐ ºÐ¾ß¿¡¼ Àü¹® Áö½ÄÀÇ Áõ°¡¿¡ ÀÖ½À´Ï´Ù. ÀǷᡤÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚÀÇ Áõ°¡, °¡Ã³ºÐ¼ÒµæÀÇ Áõ°¡, À¯¸®ÇÑ Á¤ºÎ Á¤Ã¥ÀÌ ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
º» Á¶»çÀÇ ¸ñÀûÀº ÃÖ±ÙÀÇ ´Ù¾çÇÑ ºÎ¹®°ú ±¹°¡ÀÇ ½ÃÀå ±Ô¸ð¸¦ ÆÄ¾ÇÇϰí, ÇâÈÄ ¼ö³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ ¸®Æ÷Æ®´Â Á¶»ç ´ë»ó±¹ »ê¾÷ÀÇ ÁúÀû¡¤¾çÀû Ãø¸é ¾çÃøÀ» Æ÷ÇÔ½Ã۵µ·Ï ¼³°èµÇ°í ÀÖ½À´Ï´Ù.
¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀÎ ¹× °úÁ¦ µîÀÇ Áß¿äÇÑ Ãø¸é¿¡ °üÇÑ »ó¼¼ Á¤º¸µµ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ ¹× ½ÃÀå ±¸µµÀÇ »ó¼¼ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇϱâ À§ÇÑ ¹Ì½ÃÀû ½ÃÀåÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù.
Global Drug Discovery Outsourcing Market is valued approximately USD 3.5 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 7.5% over the forecast period 2023-2030. The Drug Discovery Outsourcing Market refers to the practice of pharmaceutical and biotechnology companies outsourcing various stages of the drug discovery and development process to contract research organizations (CROs) or other specialized service providers. It involves delegating specific tasks and responsibilities related to drug discovery, such as target identification, hit-to-lead optimization, preclinical and clinical trials, and regulatory submissions, to external entities. The major driving factors for the Global Drug Discovery Outsourcing Market is rising prevalence of cardiovascular diseases and growing geriatric population. Moreover, rising initiatives by key market players and advancements in formulation is creating lucrative growth opportunity in the Global Drug Discovery Outsourcing Market over the forecast period.
The high burden of chronic diseases such as cardiovascular diseases, cancer, and respiratory diseases in the region is expected to drive market growth in the drug discovery outsourcing sector. For example, according to the CDC National Center for Health Statistics, as of 2021, 4.9% of adults aged 18 and over in the United States had coronary heart disease. This increasing prevalence of chronic diseases creates a growing demand for the development of safe and effective treatments, thereby accelerating the need for collaborations with Contract Research Organizations (CROs). Furthermore, the strategic initiatives undertaken by key players, including partnerships and acquisitions, are expected to contribute to the growth of the drug discovery outsourcing market in the region. An example of such initiatives is the collaboration agreement between Shanghai Fosun Pharmaceutical (Group) Co., Ltd and Insilico Medicine in January 2022. This partnership aimed to leverage Insilico's AI-driven drug discovery and development capabilities to advance the discovery of drugs targeting various global targets. The collaboration involved an investment of USD 13 million for R&D collaboration projects, focusing on the research and development of four biological targets. However, the high cost of Drug Discovery Outsourcing stifles market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Drug Discovery Outsourcing Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominates the drug discovery outsourcing market due to the presence of established pharmaceutical and biotechnology companies. The United States, in particular, has a robust outsourcing industry and a favorable regulatory environment, driving market growth. Factors such as advanced healthcare infrastructure, strong research and development capabilities, and increasing demand for novel therapeutics contribute to market growth in this region. The Asia Pacific region is experiencing rapid growth in the drug discovery outsourcing market. Countries such as China, India, Japan, and South Korea are emerging as major outsourcing hubs, primarily due to their large population, cost advantages, and growing expertise in life sciences. Increasing investments in healthcare infrastructure, rising disposable incomes, and favorable government policies are driving market growth in this region.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Workflow offerings of key players. The detailed segments and sub-segment of the market are explained below: